Ontology highlight
ABSTRACT:
SUBMITTER: Freidlin B
PROVIDER: S-EPMC3434989 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120806 26
Efficient development of targeted therapies that may only benefit a fraction of patients requires clinical trial designs that use biomarkers to identify sensitive subpopulations. Various randomized phase III trial designs have been proposed for definitive evaluation of new targeted treatments and their associated biomarkers (eg, enrichment designs and biomarker-stratified designs). Before proceeding to phase III, randomized phase II trials are often used to decide whether the new therapy warrant ...[more]